Cohen Fred E
SEC Form 4 insider trading activity
Cohen Fred E has filed 4 SEC Form 4 filings (4 transaction rows) across 3 companies, including CDNA, NTLA, KYTX, with disclosures dating back to 2026. 4 of those filings fall inside the rolling window. Most recent filing: Jun 16, 2026.
On the most recent filing, Cohen Fred E is listed as Director at Intellia Therapeutics, Inc. Inside the rolling window, Cohen Fred E reported 1 open-market purchase totaling $1.4M in NTLA and no open-market sales.
Companies traded
Other insiders at CDNA
Insider Buying
$1.4M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
3
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Cohen Fred E made?
Cohen Fred E has filed 4 SEC Form 4 filings (4 transaction rows) across 3 companies, including CDNA, NTLA, KYTX since 2026.
Which companies does Cohen Fred E trade?
Cohen Fred E has filed SEC Form 4 disclosures for 3 companies, including CDNA, NTLA, KYTX.
When was Cohen Fred E's most recent SEC Form 4 filing?
Cohen Fred E's most recent SEC Form 4 filing on Tracefour is dated Jun 16, 2026.
What is Cohen Fred E's total buy and sell value in the current window?
Inside the rolling retention window, Cohen Fred E bought $1.4M and sold $0 based on SEC Form 4 filings.
What was Cohen Fred E's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 150,000 NTLA shares on 2026-01-05, worth $1.4M, per SEC Form 4 filings.